Treatment with tumour necrosis factor inhibitors is not associated with a significantly increased risk of recurrent cancer among patients with rheumatoid arthritis, researchers report.
Results of a phase III trial indicate that both the immediate and extended release formulations of febuxostat reduce serum uric acid levels in patients with gout, including those with impaired renal function.
Collaboration between rheumatologists and dermatologists in a combined clinic may help improve outcomes for patients with psoriatic arthritis, study results suggest.
Results of a post-hoc analysis suggest that high early disease activity is associated with poor response to methotrexate and the occurrence of radiographic progression among patients with rheumatoid arthritis.
Source:
Ann Rheum Dis 2018; doi:10.1136/annrheumdis-2018-213502
Results of a phase III trial indicate that the infliximab biosimilar PF-06438179/GP1111 has similar efficacy, safety, and immunogenicity profiles to its reference product.
Patients with newly diagnosed systemic lupus erythematosus may experience changes to the cardiac extracellular matrix that are indicative of subclinical cardiac impairment, researchers report.
Patients with rheumatoid arthritis who have high cumulative disease activity and functional disability have an elevated 10-year risk for osteoporotic fracture, researchers report.
Results of an open-label randomized trial suggest that rituximab may be an appropriate alternative to cyclophosphamide for treating lung and skin disease associated with systemic sclerosis.
Study results suggest that patients with primary Sjögren’s syndrome, and those with similar symptoms, may experience dysbiosis of the buccal mucosa microbiome.
Phase II trial results published in The Lancet suggest that adding the Janus kinase 1 and 2 inhibitor baricitinib to standard care may be beneficial for patients with systemic lupus erythematosus.
Treatment with the interleukin-17A inhibitor secukinumab is associated with a reduction in synovial inflammation among patients with psoriatic arthritis, results of the PSARTROS study suggest.
Study results indicate that patients with severe juvenile idiopathic arthritis who start biologic DMARDs within 2 years of symptom onset have better long-term outcomes than those who begin treatment later.
The proportion of patients initiating osteoporosis medication following hip fracture has declined in recent years, despite treatment reducing subsequent fracture risk, analysis of a US medical claims database suggests.
Patients who develop gout before the age of 40 years may experience similar metabolic comorbidities and joint complications as their counterparts with later-onset disease, researchers report.
Researchers have a developed a model including clinical and psychosocial factors to predict which patients with rheumatoid arthritis are unlikely to respond to methotrexate treatment.